www.bna.com Pharmaceutical Law & Industry Report
HomeIndexTable of CasesFeedbackwww.bna.com

Printable version (PDF) 

INDEX
Vol. 7, Nos. 1-26 pp. 1-758
Jan. 2-Jun. 26 , 2009

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

    ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)
      – Bioequivalence
        – – Data submission, FDA issues draft guidance, 471
        – – Product specific studies, FDA issues final recommendations, 685
        – – Studies, FDA issues rule, 98
      – Clobel patent infringement alleged (N.D. Tex.), 63
      – Generic drugs
        – – Allegra-D maker tries to block generic (D.N.J.), 119
        – – Cardene, generic ANDA challenged (D.N.J.), 401
        – – Doryx generic ANDAs challenged as infringement, 14
        – – Fortamet, generic ANDA challenged (D. Del.), 97
        – – Truvada V drug ANDA infringes patent (S.D.N.Y.), 10
      – Lotrel low-dose ANDA challenged as infringement (D.N.J.), 13; dismissed, 201
      – Pataday
      – Withdrawals not due to safety or effectiveness, FDA says, 19; 19 drugs withdrawn, 715
    ACCREDITATION AND CERTIFICATION
      – Pfizer study subject protection program accredited, 417
    ACCUTANE
      – Acne drug blamed for inflammatory bowel disease, new trial ordered (N.J. Super. Ct.), 313
      – Failure-to-warn of suicide risk, maker wins summary judgment (11th Cir.), 705
    ACTIMMUNE
      – Class action over off-label use marketing dismissed (N.D. Cal.), 583
      – Indictment of CEO over off-label use promotion upheld (N.D. Cal.), 675
    ACTONEL
      – Bone-blocking drug, generic version challenged (D. Del.), 150
      – Osteoporosis drug patent upheld against generic maker (Fed. Cir.), 581
    ACULAR
      – Eye inflammation treatment patent upheld (U.S., rev den), 117
    ADVERSE EFFECTS
      – Mixing prescription and OTC drugs, adverse reactions in seniors possible, 21
    ADVERSE EVENTS
      – Canada, reporting changes considered, 721
      – Genetic basis for certain events, FDA releases data, 182
      – Raptiva, FDA issues advisory, 233
      – Toll-free number on medication guides, FDA issues guidance, 686
    ADVERTISING
      – Avodart, FDA says TV ad is misleading, 271
      – Brazil revises rules, 27
      – Depakote, FDA tells maker to pull misleading materials, 159
      – GSK plans $400M charge, federal probe cited, 160
      – HRT claims, jurisdiction lacking over ad firms with insufficient W.Va. contacts (E.D. Ark.), 367
      – Humira ad broadens approved indication and minimizes risks, FDA says, 21
      – Nexium, false advertising class action remanded (3rd Cir.), 587
      – Protonix, generic advertising challenged (E.D. Mich.), 554
      – Risk information
        – – Draft guidance issued by FDA, 618
        – – Lacking from many Internet ads, 413
      – Ultram ER web video called misleading by FDA, 623
      – Velcade maker accused of overstating efficacy, 746
      – Yaz maker to submit TV ads to FDA, 189
    AFINITOR
      – Approved for kidney cancer, 383
    AIDS AND HIV
      – IDX889 licensing, In Brief, 191
      – IQP-0410, In Brief, 49
      – Kaletra, price cut in Mexico, 387
      – Specialist firm planned, In Brief, 486
    ALABAMA
      – Medicaid
        – – E-prescribing system announced, 648
        – – Pricing
          – – – 5 firms settle with state (Ala. Cir. Ct.), 40
          – – – Jury awards $78.4M (Ala. Cir. Ct.), 227
          – – – More firms settle (Ala. Cir. Ct.), 610
    ALDARA
      – Skin cancer cream blamed for severe symptoms, claim time-barred (D. Utah), 257
    ALLEGRA-D
      – Allergy drug maker tries to block generic (D.N.J.), 119
    ANALYSIS & PERSPECTIVE
      – De-identified health information and state regulation, 422
      – Federal preemption in drug and device suits, 106
      – Foreign Corrupt Practices Act compliance, 215
      – Patents
        – – Reversing patent settlements, 749
        – – Risk evaluation and mitigation strategy patents, 28
      – Phenergan failure to warn claim, 353; effect on preemption defense, 658
      – Trademarks, proving use, 52
    ANDAs
    ANDROGEL
      – Class actions seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
      – Testosterone replacement drug, FTC accuses generic and brand name makers colluding to delay (C.D. Cal.), 145
    ANTI-KICKBACK LAWS
      – UN Oil for Food Program, Danish firm settles charges (D.D.C.), 558
    ANTIBIOTICS
      – Cephem compound double patent challenge, summary judgment vacated (Fed. Cir.), 433
      – Doryx
      – Flucloxacillin associated with liver damage, 652
      – HGS and Morphotek, In Brief, 386
      – Plectasin NZ2114, In Brief, 25
      – Trovan maker accused of violating international norms (2nd Cir.), 147
    ANTIDEPRESSANTS
      – Consolidation of product liability claims denied (D. Mo.), 639
      – Failure-to-warn of suicide risk, preemption ruling remanded (U.S.), 280; vacated and remanded (3rd Cir.), 497; briefs filed, 498
      – Lexapro approved for adolescents, 350
      – Paxil
    ANTITRUST
      – AndroGel, class actions seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
      – Apotex counterclaims against Daiichi dismissed (D.N.J.), 636
      – BMS to settle with states over court order violations, 12
      – Cipro settlement challenged (U.S., rev den), 730
      – CVS Caremark merger, FTC probe sought, 565; pharmacists group alleges monopoly, 565
      – False statements, former exec ordered to write book about case (D.D.C.), 679
      – Hytrin monopoly claim remanded (9th Cir.), 91
      – K-Dur purchasers class certified (D.N.J.), 38; special master recommends dropping, 175
      – Leibowitz as FTC chair, more scrutiny predicted for drug industry, 261
      – Nifedipine direct purchasers class action certified (D.C. Cir.), 229
      – Ovcon settlement reached (D.D.C.), 12
      – Plavix suit, former executive pleads guilty to false statements (D.D.C.), 401
      – Reverse payment deals
        – – Position of Obama administration sought, 476
        – – Targeted by FTC, 372
      – Tricor, consumer suit over generic delay, settlement approved (D. Del.), 500
      – Wellbutrin, direct purchaser antitrust suit may proceed (E.D. Pa.), 308
    APPLICATIONS
      – Acetavance, In Brief, 596
      – Acurox, In Brief, 51; 272; 747
      – Afresa, In Brief, 324; new application, In Brief, 595
      – Apirin-ulcer drug combo, In Brief, 541
      – AR-12, In Brief, 570
      – AR-42, In Brief, 324
      – Arzerra, In Brief, 164; called safe and effective by FDA panel, 649; review extended, In Brief, 720
      – Bepreve, In Brief, 105
      – Botox, In Brief, 626
      – Cefazolin, In Brief, 655
      – Certriad, In Brief, 692
      – Cervarix, In Brief, 385
      – Cimzia, FDA wants more data, 46
      – Cinryze
      – Colitis drug, FDA wants more data, 46
      – Cymbalta, In Brief, 655
      – Denosumab, In Brief, 24
      – Diabetes treatment, FDA to apply guidance, 295
      – Durezol, In Brief, 324
      – DX-88, In Brief, 385
      – Erbitux, In Brief, 134
      – Exenatide, In Brief, 541
      – Fampridine-SR, In Brief, 385; 571
      – Fenretinide, In Brief, 450
      – Flutiform, In Brief, 627; FDA may need more data, In Brief, 691
      – Ganciclovir ophthalmic gel, In Brief, 134
      – Genasense, In Brief, 297
      – GGTI-2418, In Brief, 192; 271
      – Imitrex, In Brief, 213
      – Intelence, In Brief, 192
      – Intermezzo, In Brief, 719
      – Invega, In Brief, 191
      – Isolagen Therapy, In Brief, 298
      – LiquiXR, In Brief, 570
      – Loramyc, In Brief, 720
      – Lucassin, In Brief, 719
      – Lumizyme, FDA seeks more information, 270
      – MonoSol XR, In Brief, 451
      – Nexium, In Brief, 25
      – NGX-4019, In Brief, 25
      – Nonsteroidal anti-inflammatory drug, 418
      – Ondansetron ODFS, In Brief, 691
      – Onglyza timeline extended, 513
      – Onrigin, In Brief, 212; application accepted, 486
      – Pegloticase, In Brief, 50; 51
      – Pixantrone, In Brief, 134; rolling submission, In Brief, 451; priority review sought, In Brief, 747
      – PN 400, In Brief, 596
      – PolyHeme not approved, In Brief, 542
      – Reloxin, In Brief, 78
      – Restanza called safe, but not effective by FDA panel, 649
      – Rexin-G, In Brief, 720
      – Rezonic, In Brief, 747
      – Risperdal, In Brief, 213
      – Rituxan, In Brief, 595
      – ROX-888, In Brief, 192
      – Saphris, In Brief, 105; 238
      – Seroquel XR, In Brief, 24
      – Stelara, In Brief, 626
      – Sunitinib, In Brief, 595
      – Surfaxin, FDA wants more data, 477
      – Symbicort, In Brief, 418
      – Tarceva, In Brief, 352
      – Tykerb, In Brief, 384
      – Tyvaso, In Brief, 324; 515
      – Ustekinumab, In Brief, 25
      – Xiaflex, In Brief, 515
      – XP12B, In Brief, 419
      – Zegerid, In Brief, 164
      – Zenpep, In Brief, 747
      – Zogenix, In Brief, 212
      – Zyprexa, In Brief, 78
    APPROVALS
      – ACTOplus met, In Brief, 569
      – Adcira, In Brief, 626
      – Apidra SoloSTAR, In Brief, 272
      – Atryn approved by FDA, 190
      – Avastin, FDA panel favors approval for brain cancer, 381; approved, 540
      – Average approval time down at FDA, development time up, 74
      – Axert, In Brief, 692
      – Azor, In Brief, 570
      – Besivance approved, 651
      – Cimzia, In Brief, 596
      – CIP-Tramadol ER, In Brief, 212
      – Citizen petitions, FDA issues draft guide, 122
      – Coartem tablets approved for malaria infections, 416
      – Creon, In Brief, 541
      – Degarelix approved, 22
      – DX-88, FDA panel favors approval, 188
      – Fanapt approved for adult schizophrenia with warning, 539
      – Gelnique, In Brief, 134
      – Generics
      – Gleevec approved, 23
      – Ibuprofen Injectable dosage approved by FDA, 717
      – Ilaris, In Brief, 748
      – Kapidex, In Brief, 164
      – Krystexxa, In Brief, 719
      – Lamictal XR, In Brief, 656
      – Lexapro approved for adolescents, 350
      – Multaq, FDA panel favors approval, 350
      – Nexterone, In Brief, 50
      – Onglyza, FDA panel favors approval, 414
      – Prasugrel, FDA panel favors approval, 159; consumer group opposes, 649
      – Provenge, politically-motivated delay in approval alleged, dismissal affirmed (U.S., rev den), 61
      – Reclast, In Brief, 656
      – RiaSTAP approved for bleeding in patients with congenital fibrinogen deficiency, 102
      – Rivaroxaban gets favorable review from FDA panel, 351; gets complete response letter, 650
      – Ryzolt, In Brief, 51
      – Sabril cleared by FDA panel, 73
      – Samsca, In Brief, 627
      – Sanvar, In Brief, 627
      – Savella, In Brief, 105
      – Silenor application rejected by FDA, 446
      – Simponi for arthritis, 513
      – Symbicort, In Brief, 272
      – Symbyax, In Brief, 352
      – Tygacil, In Brief, 352
      – Uloric, In Brief, 212
      – Vancomycin, In Brief, 570
      – Vectical, In Brief, 163
      – Zingo, In Brief, 77
      – Zipsor, In Brief, 748
      – Zolpimist, In Brief, 24
      – Zyprexa, In Brief, 352
    ARANESP
      – Anemia drug off-label use class action dismissed (C.D. Cal.), 730
      – Illegal marketing alleged (D. Mass.), 255
    ARBITRATION
      – Remicide distribution agreement, arbitration sought, 622
    ARZERRA
      – Leukemia drug, In Brief, 164; called safe and effective by FDA panel, 649
    ATRYN
      – Anticoagulant approved by FDA, 190
    ATTORNEYS
      – Falsified drug paperwork (D.N.H.), In Brief, 617
      – Fen-phen settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467
    AVASTIN
      – Brain cancer treatment, FDA panel favors approval, 381; approved, 540
      – CalPERS approves for ovarian cancer, 296
    AVODART
      – Prostate treatment, FDA says TV ad is misleading, 271
    AZOPT
      – Eye drug maker alleges infringement (E.D. Tex.), 119

Contact the Webmaster at webmaster@bna.com
1801 S. Bell Street, Arlington, VA 22202 - Phone: 1-800-372-1033

Copyright © The Bureau of National Affairs, Inc. All Rights Reserved.